|
|
||||||||
and Bcl-2




Departments of
* Pathology,
Surgery, and
Immunology, University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute, and
Department of Molecular Biology and Biochemistry, University of Pittsburgh, Pennsylvania
Correspondence: Galina V. Shurin, Ph.D., Clinical Immunopathology, University of Pittsburgh Medical Center, 5725 CHP MT, 200 Lothrop Street, Pittsburgh, PA 15213. E-mail: shuringv{at}msx.upmc.edu
It has been recently demonstrated that dendritic cells (DC) coincubated with interleukin (IL)-15 express high levels of the Bcl-2 family of proteins and display an increased resistance to tumor-induced apoptotic death. Here, the phenotype, functions, and survival of human DC transduced with adenoviral vector encoding the human IL-15 gene were studied. The transduction of DC with the IL-15 gene resulted in a significant elevation of expression of CD83, CD86, and CD40 molecules, which was blocked by anti-IL-15 monoclonal antibodies. This effect was also accompanied by an increased production of IL-12 and stimulated ability of DC to induce T cell proliferation. Furthermore, transduction of DC with the IL-15 gene significantly increased their resistance to prostate cancer-induced apoptosis: Overexpression of IL-15 on DC blocked tumor-induced inhibition of Bcl-2 expression and prolonged DC survival after coincubation with tumor cells. Finally, overexpression of IL-15 in DC was associated with a higher level of expression of IL-15 receptor
chain mRNA. In summary, these results suggest that transduction of DC with the IL-15 gene markedly stimulates DC function and protects them from tumor-induced apoptosis.
Key Words: apoptosis immunosuppression prostate cancer
This article has been cited by other articles:
![]() |
M. M. Moretto, E. M. Lawlor, and I. A. Khan Aging Mice Exhibit a Functional Defect in Mucosal Dendritic Cell Response against an Intracellular Pathogen J. Immunol., December 1, 2008; 181(11): 7977 - 7984. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. U. Saikh, T. L. Kissner, S. Nystrom, G. Ruthel, and R. G. Ulrich Interleukin-15 Increases Vaccine Efficacy through a Mechanism Linked to Dendritic Cell Maturation and Enhanced Antibody Titers Clin. Vaccine Immunol., January 1, 2008; 15(1): 131 - 137. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. W. Blaser, N. R. Schwind, S. Karol, D. Chang, S. Shin, S. Roychowdhury, B. Becknell, A. K. Ferketich, D. F. Kusewitt, B. R. Blazar, et al. Trans-presentation of donor-derived interleukin 15 is necessary for the rapid onset of acute graft-versus-host disease but not for graft-versus-tumor activity Blood, October 1, 2006; 108(7): 2463 - 2469. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. L. Tourkova, G. V. Shurin, G. S. Chatta, L. Perez, J. Finke, T. L. Whiteside, S. Ferrone, and M. R. Shurin Restoration by IL-15 of MHC Class I Antigen-Processing Machinery in Human Dendritic Cells Inhibited by Tumor-Derived Gangliosides J. Immunol., September 1, 2005; 175(5): 3045 - 3052. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-S. Park, S.-O. Yoon, R. J. Armitage, and Y. S. Choi Follicular Dendritic Cells Produce IL-15 That Enhances Germinal Center B Cell Proliferation in Membrane-Bound Form J. Immunol., December 1, 2004; 173(11): 6676 - 6683. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Roychowdhury, K. F. May Jr., K. S. Tzou, T. Lin, D. Bhatt, A. G. Freud, M. Guimond, A. K. Ferketich, Y. Liu, and M. A. Caligiuri Failed Adoptive Immunotherapy with Tumor-Specific T Cells: Reversal with Low-Dose Interleukin 15 but not Low-Dose Interleukin 2 Cancer Res., November 1, 2004; 64(21): 8062 - 8067. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Perrotta, S. Falcone, A. Capobianco, A. Camporeale, C. Sciorati, C. D. Palma, A. Pisconti, P. Rovere-Querini, M. Bellone, A. A. Manfredi, et al. Nitric Oxide Confers Therapeutic Activity to Dendritic Cells in a Mouse Model of Melanoma Cancer Res., June 1, 2004; 64(11): 3767 - 3771. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |